Cell penetrating peptides: the potent multi-cargo intracellular carriers

References

• Eiríksdóttir E, Konate K, Langel Ü, et al. Secondary structure of cell-penetrating peptides controls membrane interaction and insertion. Biochim Biophys Acta. 2010;1798:1119–1128.
   PubMed Web of Science ®Google Scholar
• Ramsey JD, Flynn NHJP. Cell-penetrating peptides transport therapeutics into cells. Pharmacol Ther. 2015;154:78–86.
   PubMed Web of Science ®Google Scholar
• Ma JL, Wang H, Wang YL, et al. Enhanced peptide delivery into cells by using the synergistic effects of a cell-penetrating peptide and a chemical drug to alter cell permeability. Mol Pharm. 2015;12:2040–2048.
   PubMed Web of Science ®Google Scholar
• Jafari S, Dizaj SM, Adibkia K. Cell-penetrating peptides and their analogues as novel nanocarriers for drug delivery. Bioimpacts. 2015;5:103.
   PubMed Web of Science ®Google Scholar
• Bolhassani A, Jafarzade BS, Mardani G. In vitro and in vivo delivery of therapeutic proteins using cell penetrating peptides. Peptides. 2017;87:50–63.
   PubMed Web of Science ®Google Scholar
• Koren E, Torchilin VP. Cell-penetrating peptides: breaking through to the other side. Trends Mol Med. 2012;18:385–393.
   PubMed Web of Science ®Google Scholar
• Kalafatovic D, Giralt E. Cell-penetrating peptides: design strategies beyond primary structure and amphipathicity. Molecules. 2017;22:1929.
   Web of Science ®Google Scholar
• Gautam A, Chaudhary K, Kumar R, et al. Computer-aided virtual screening and designing of cell-penetrating peptides. Methods Mol Biol. 2015;1324:59–69.
   PubMedGoogle Scholar
• Tang J, Ning J, Liu X, et al. A novel amino acid sequence-based computational approach to predicting cell-penetrating peptides. Curr Comput Aided Drug Des. 2019;15(3):206–211.
   PubMed Web of Science ®Google Scholar
• Gautam A, Chaudhary K, Kumar R, et al. In silico approaches for designing highly effective cell penetrating peptides. J Transl Med. 2013;11:74.
   PubMed Web of Science ®Google Scholar
• Langel U. Cell-penetrating peptides: processes and applications. CRC press: Pharmacology and Toxicology Series; 2002.
   Google Scholar
• Brasseur R, Divita G. Happy birthday cell penetrating peptides: already 20 years. Biochim Biophys Acta. 2010;1798:2177–2181.
   PubMed Web of Science ®Google Scholar
• Sugita T, Yoshikawa T, Mukai Y, et al. Improved cytosolic translocation and tumor-killing activity of Tat-shepherdin conjugates mediated by co-treatment with Tat-fused endosome-disruptive HA2 peptide. Biochem Biophys Res Commun. 2007;363:1027–1032.
   PubMed Web of Science ®Google Scholar
• Lyu L, Huang LQ, Huang T, et al. Cell-penetrating peptide conjugates of gambogic acid enhance the antitumor effect on human bladder cancer EJ cells through ROS-mediated apoptosis. Drug Des Devel Ther. 2018;12:743.
   PubMed Web of Science ®Google Scholar
• Wender PA, Mitchell DJ, Pattabiraman K, et al. The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc Nat Acad Sci. 2000;97:13003–13008.
   PubMed Web of Science ®Google Scholar
• Futaki S, Suzuki T, Ohashi W, et al. Arginine-rich peptides: an abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J Biol Chem. 2001;276:5836–5840.
   PubMed Web of Science ®Google Scholar
• Joliot A, Pernelle C, Deagostini-Bazin H, et al. Antennapedia homeobox peptide regulates neural morphogenesis. Proc Nat Acad Sci. 1991;88:1864–1868.
   PubMed Web of Science ®Google Scholar
• Nan YH, Park IS, Hahm KS, et al. Antimicrobial activity, bactericidal mechanism and LPS neutralizing activity of the cell penetrating peptide pVEC and its analogs. J Pept Sci. 2011;17:812–817.
   PubMed Web of Science ®Google Scholar
• Johansson HJ, El-Andaloussi S, Holm T, et al. Characterization of a novel cytotoxic cell penetrating peptide derived from p14ARF protein. Mol Ther. 2008;16:115–123.
   Web of Science ®Google Scholar
• Soomets U, Hallbrink M, Zorko M, et al. From galanin and mastoparan to galparan and transportan. Curr Top Pept Prot Res. 1997;2:83–113.
   Google Scholar
• Lin CH, Hou RF, Shyu CL, et al. In vitro activity of mastoparan-AF alone and in combination with clinically used antibiotics against multiple-antibiotic-resistant Escherichia coli isolates from animals. Peptides. 2012;36:114–120.
   PubMed Web of Science ®Google Scholar
• Yandek LE, Pokorny A, Florén A, et al. Mechanism of the cell-penetrating peptide transportan 10 permeation of lipid bilayers. Biophys J. 2007;92:2434–2444.
   PubMed Web of Science ®Google Scholar
• Vazquez E, Ferrer-Miralles N, Mangues R, et al. Modular protein engineering in emerging cancer therapies. Curr Pharm Des. 2009;15:893–916.
   PubMed Web of Science ®Google Scholar
• Zorko M, Langel U. Cell-penetrating peptides: mechanism and kinetics of cargo delivery. Adv Drug Deliv Rev. 2005;57:529–545.
   PubMed Web of Science ®Google Scholar
• De Coupade C, Fittipaldi A, Chagnas V, et al. Novel human-derived cellpenetrating peptides for specific subcellular delivery of therapeutic biomolecules. Biochem J. 2005;390:407–418.
   PubMed Web of Science ®Google Scholar
• McKay T, Reynolds P, Jezzard S, et al. Secretin-mediated gene delivery, a specific targeting mechanism with potential for treatment of biliary and pancreatic disease in cystic fibrosis. Mol Ther. 2002;5:447–454.
   PubMed Web of Science ®Google Scholar
• Zhang X, Oglęcka K, Sandgren S, et al. Dual functions of the human antimicrobial peptide LL-37-target membrane perturbation and host cell cargo delivery. Biochimi Biophys Acta (BBA) Biomembr. 2010;1798:2201–2208.
   PubMed Web of Science ®Google Scholar
• Duchardt F, Ruttekolk IR, Verdurmen WPR, et al. A cell-penetrating peptide derived from human lactoferrin with conformation-dependent uptake efficiency. J Biol Chem. 2009;284:36099–36108.
   PubMed Web of Science ®Google Scholar
• Tian H, Lin L, Chen J, et al. RGD targeting hyaluronic acid coating system for PEI-PBLG polycation gene carriers. J Control Release. 2011;155:47–53.
   PubMed Web of Science ®Google Scholar
• Sadler K, Eom KD, Yang JL, et al. Translocating proline-rich peptides from the antimicrobial peptide bactenecin 7. Biochemistry. 2002;41:14150–14157.
   PubMed Web of Science ®Google Scholar
• Cho JH, Sung BH, Kim SC. Buforins: histone H2A-derived antimicrobial peptides from toad stomach. Biochim Biophys Acta. 2009;1788:1564–1569.
   PubMed Web of Science ®Google Scholar
• Hoyer J, Schatzschneider U, Schulz-Siegmund M, et al. Dimerization of a cell-penetrating peptide leads to enhanced cellular uptake and drug delivery. Beilstein J Org Chem. 2012;8:1788–1797.
   PubMed Web of Science ®Google Scholar
• Steinberg DA, Hurst MA, Fujii CA, et al. Protegrin-1: a broad-spectrum, rapidly microbicidal peptide with in vivo activity. Antimicrob Agents Chemother. 1997;41:1738–1742.
   PubMed Web of Science ®Google Scholar
• Magzoub M, Sandgren S, Lundberg P, et al. N-terminal peptides from unprocessed prion proteins enter cells by macropinocytosis. Biochem Biophys Res Commun. 2006;348:379–385.
   PubMed Web of Science ®Google Scholar
• Olson ES, Whitney MA, Friedman B, et al. In vivo fluorescence imaging of atherosclerotic plaques with activatable cell-penetrating peptides targeting thrombin activity. Integr Biol. 2012;4:595–605.
   Google Scholar
• Elliott G, O’Hare P. Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell. 1997;88:223–233.
   PubMed Web of Science ®Google Scholar
• Oehlke J, Krause E, Wiesner B, et al. Extensive cellular uptake into endothelial cells of an amphipathic β-sheet forming peptide. FEBS Lett. 1997;415:196–199.
   PubMed Web of Science ®Google Scholar
• Nakayama F, Yasuda T, Umeda S, et al. Fibroblast growth factor-12 translocation into intestinal epithelial cells is dependent on a novel cell-penetrating peptide domain: involvement of internalization in the in vivo role of exogenous FGF12. J Biol Chem. 2011;286:25823–25834.
   PubMed Web of Science ®Google Scholar
• Rhee M, Davis P. Mechanism of uptake of C105Y, a novel cell-penetrating peptide. J Biol Chem. 2006;281:1233–1240.
   PubMed Web of Science ®Google Scholar
• Watkins CL, Brennan P, Fegan C, et al. Cellular uptake, distribution and cytotoxicity of the hydrophobic cell penetrating peptide sequence PFVYLI linked to the proapoptotic domain peptide PAD. J Control Release. 2009;140:237–244.
   PubMed Web of Science ®Google Scholar
• Gao S, Simon MJ, Hue CD, et al. An unusual cell penetrating peptide identified using a plasmid display-based functional selection platform. ACS Chem Biol. 2011;6:484–491.
   PubMed Web of Science ®Google Scholar
• Gao C, Mao S, Ditzel HJ, et al. A cell-penetrating peptide from a novel pVII-pIX phage-displayed random peptide library. Bioorg Med Chem. 2002;10:4057–4065.
   PubMed Web of Science ®Google Scholar
• Jha D, Mishra R, Gottschalk S, et al. CyLoP-1: a novel cysteine-rich cell-penetrating peptide for cytosolic delivery of cargoes. Bioconjug Chem. 2011;22:319–328.
   PubMed Web of Science ®Google Scholar
• Lopes LB, Flynn C, Komalavilas P, et al. Inhibition of HSP27 phosphorylation by a cell-permeant MAPKAP Kinase 2 inhibitor. Biochem Biophys Res Commun. 2009;382:535–539.
   PubMed Web of Science ®Google Scholar
• Liou JS, Liu BR, Martin AL, et al. Protein transduction in human cells is enhanced by cell-penetrating peptides fused with an endosomolytic HA2 sequence. Peptides. 2012;37:273–284.
   PubMed Web of Science ®Google Scholar
• Matsumoto T. Membrane destabilizing activity of influenca virus hemagglutinin-based synthetic peptide: implication of critical glycine residue in fusion peptide. Biophys Chem. 1999;79:153–162.
   PubMed Web of Science ®Google Scholar
• Oehlke J, Lorenz D, Wiesner B, et al. Model amphipathic peptides. In: Langel Ü, editor. Handbook of cell-penetrating peptides. Boca Raton, London, New York: CRC-Press; 2007. p. 43–60.
   Google Scholar
• Murata M, Sugahara Y, Takahashi S, et al. pH-dependent membrane fusion activity of a synthetic twenty amino acid peptide with the same sequence as that of the hydrophobic segment of influenza virus hemagglutinin. J Biochem. 1987;102:957–962.
   PubMed Web of Science ®Google Scholar
• Neundorf I, Rennert R, Hoyer J, et al. Fusion of a short HA2-derived peptide sequence to cell penetrating peptides improves cytosolic uptake, but enhances cytotoxic activity. Pharmaceutics. 2009;2:49–65.
   Google Scholar
• Yamada T, Das Gupta TK, Beattie CW. p28, an anionic cell-penetrating peptide, increases the activity of wild type and mutated p53 without altering its conformation. Mol Pharm. 2013;10:3375–3383.
   PubMed Web of Science ®Google Scholar
• Mi Z, Lu X, Mai JC, et al. Identification of a synovial fibroblast-specific protein transduction domain for delivery of apoptotic agents to hyperplastic synovium. Mol Ther. 2003;8:295–305.
   PubMed Web of Science ®Google Scholar
• Chen Z, Zhang P, Cheetham AG, et al. Controlled release of free doxorubicin from peptide-drug conjugates by drug loading. J Control Release. 2014;191:123–130.
   PubMed Web of Science ®Google Scholar
• Oehlke J, Lorenz D, Wiesner B, et al. Review: studies on the cellular uptake of substance P and lysine-rich, KLA-derived model peptides. J Mol Recognit. 2005;18:50–59.
   PubMed Web of Science ®Google Scholar
• Wolf Y, Pritz F, Abes S, et al. Structural requirements for cellular uptake and antisense activity of peptide nucleic acids conjugated with various peptides. Biochemistry. 2006;45:14944–14954.
   PubMed Web of Science ®Google Scholar
• Oehlke J, Scheller A, Wiesner B, et al. Cellular uptake of an α-helical amphipathic model peptide with the potential to deliver polar compounds into the cell interior non-endocytically. Biochim Biophys Acta. 1998;1414:127–139.
   PubMed Web of Science ®Google Scholar
• Repke A, Bienert M. Mast cell activation-a receptor-independent mode of substance P action. FEBS Lett. 1987;221:236–240.
   PubMed Web of Science ®Google Scholar
• Lamaziere A, Burlina F, Wolf C, et al. Non-metabolic membrane tubulation and permeability induced by bioactive peptides. PLoS One. 2007;2:e201.
   PubMed Web of Science ®Google Scholar
• Rodrigues M, de la Torre BG, Radis-Baptista G, et al. Efficient cellular delivery of β-galactosidase mediated by NrTPs, a new family of cell-penetrating peptides. Bioconjugate Chem. 2011;22:2339–2344.
   PubMed Web of Science ®Google Scholar
• Nascimento FD, Hayashi MAF, Kerkis A, et al. Crotamine mediates gene delivery into cells through binding to heparan sulfate proteoglycans. J Biol Chem. 2007;282:21349–21360.
   PubMed Web of Science ®Google Scholar
• Radis-Baptista G, Kerkis I. Crotamine, a small basic polypeptide myotoxin from rattlesnake venom with cell-penetrating properties. Curr Pharmacol Des. 2011;17:4351–4361.
   PubMed Web of Science ®Google Scholar
• Jiang T, Olson ES, Nguyen QT, et al. Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proc Nat Acad Sci. 2004;101:17867–17872.
   PubMed Web of Science ®Google Scholar
• Guterstam P, Madani F, Hirose H, et al. Elucidating cell-penetrating peptide mechanisms of action for membrane interaction, cellular uptake, and translocation utilizing the hydrophobic counter-anion pyrenebutyrate. Biochimi Biophys Acta (BBA) Biomembr. 2009;1788:2509–2517.
   PubMed Web of Science ®Google Scholar
• Rujitanaroj PO, Jao B, Yang J, et al. Controlling fibrous capsule formation through long-term down-regulation of collagen type I (COL1A1) expression by nanofiber-mediated siRNA gene silencing. Acta Biomater. 2013;9:4513–4524.
   PubMed Web of Science ®Google Scholar
• Bartlett RL, Panitch A. Thermosensitive nanoparticles with pH-triggered degradation and release of anti-inflammatory cell-penetrating peptides. Biomacromolecules. 2012;13:2578–2584.
   PubMed Web of Science ®Google Scholar
• Henriques ST, Costa J, Castanho MA. Translocation of β-galactosidase mediated by the cell-penetrating peptide pep-1 into lipid vesicles and human HeLa cells is driven by membrane electrostatic potential. Biochemistry. 2005;44:10189–10198.
   PubMed Web of Science ®Google Scholar
• Lim KJ, Sung BH, Shin JR, et al. A cancer specific cell-penetrating peptide, BR2, for the efficient delivery of an scFv into cancer cells. PLoS One. 2013;8:e66084.
   PubMed Web of Science ®Google Scholar
• Ma J, Xu J, Guan L, et al. Cell-penetrating peptides mediated protein cross-membrane delivery and its use in bacterial vector vaccine. Fish Shellfish Immunol. 2014;39:8–16.
   PubMed Web of Science ®Google Scholar
• Liu BR, Huang YW, Aronstam RS, et al. Identification of a short cell-penetrating peptide from bovine lactoferricin for intracellular delivery of DNA in human A549 cells. PLoS One. 2016;11:e0150439.
   PubMed Web of Science ®Google Scholar
• Morris MC, Gros E, Aldrian-Herrada G, et al. A non-covalent peptide-based carrier for in vivo delivery of DNA mimics. Nucleic Acids Res. 2007;35:e49.
   PubMed Web of Science ®Google Scholar
• Mai JC, Shen H, Watkins SC, et al. Efficiency of protein transduction is cell type-dependent and is enhanced by dextran sulfate. J Biol Chem. 2002;277:30208–30218.
   PubMed Web of Science ®Google Scholar
• Chu D, Xu W, Pan R, et al. Rational modification of oligoarginine for highly efficient siRNA delivery: structure-activity relationship and mechanism of intracellular trafficking of siRNA, nanomedicine: nanotechnology. Biol Med. 2015;11:435–446.
   Google Scholar
• Zhang H, Curreli F, Waheed AA, et al. Dual-acting stapled peptides target both HIV-1 entry and assembly. Retrovirology. 2013;10:136.
   PubMed Web of Science ®Google Scholar
• Eggimann GA, Blattes E, Buschor S, et al. Designed cell penetrating peptide dendrimers efficiently internalize cargo into cells. Chem Comm. 2014;50:7254–7257.
   PubMed Web of Science ®Google Scholar
• Fernández-Carneado J, Kogan MJ, Pujals S, et al. Amphipathic peptides and drug delivery. Pept Sci Original Res Biomolecules. 2004;76:196–203.
   Google Scholar
• Mano M, Henriques A, Paiva A, et al. Interaction of S413-PV cell penetrating peptide with model membranes: relevance to peptide translocation across biological membranes. J Pept Sci. 2007;13:301–313.
   PubMed Web of Science ®Google Scholar
• Kizil C, Iltzsche A, Thomas AK, et al. Efficient cargo delivery into adult brain tissue using short cell-penetrating peptides. PLoS One. 2015;10:e0124073.
   PubMed Web of Science ®Google Scholar
• Wagner E, Plank C, Zatloukal K, et al. Influenza virus hemagglutinin HA-2 N-terminal fusogenic peptides augment gene transfer by transferrin-polylysine-DNA complexes: toward a synthetic virus-like gene-transfer vehicle. Proc Natl Acad Sci USA. 1992;89:7934–7938.
   PubMed Web of Science ®Google Scholar
• Singh D, Bisland SK, Kawamura K, et al. Peptide-based intracellular shuttle able to facilitate gene transfer in mammalian cells. Bioconjug Chem. 1999;10:745–754.
   PubMed Web of Science ®Google Scholar
• Niidome T, Ohmori N, Ichinose A, et al. Binding of cationic α-helical peptides to plasmid DNA and their gene transfer abilities into cells. J Biol Chem. 1997;272:15307–15312.
   PubMed Web of Science ®Google Scholar
• Suzuki K, Murtuza B, Brand NJ, et al. Enhanced effect of myocardial gene transfection by VP22-mediated intercellular protein transport. J Mol Cell Cardiol. 2004;36:603–606.
   PubMed Web of Science ®Google Scholar
• Zhang M, Zhao X, Geng J, et al. Wang, efficient penetration of Scp01-b and its DNA transfer abilities into cells. J Cell Physiol. 2019;234:6539–6547.
   PubMed Web of Science ®Google Scholar
• Davidson TJ, Harel S, Arboleda VA, et al. Highly efficient small interfering RNA delivery to primary mammalian neurons induces microRNA-like effects before mRNA degradation. J Neurosci. 2004;24:10040–10046.
   PubMed Web of Science ®Google Scholar
• Andaloussi SE, Lehto T, Mäger I, et al. Design of a peptide-based vector, PepFect6, for efficient delivery of siRNA in cell culture and systemically in vivo. Nucleic Acids Res. 2011;39:3972–3987.
   PubMed Web of Science ®Google Scholar
• Crombez L, Aldrian-Herrada G, Konate K, et al. A new potent secondary amphipathic cell-penetrating peptide for siRNA delivery into mammalian cells. Mol Ther. 2009;17:95–103.
   PubMed Web of Science ®Google Scholar
• Gooding M, Browne LP, Quinteiro FM, et al. siRNA delivery: from lipids to cell penetrating peptides and their mimics. Chem Biol Drug Des. 2012;80:787–809.
   PubMed Web of Science ®Google Scholar
• Moschos SA, Jones SW, Perry MM, et al. Lung delivery studies using siRNA conjugated to TAT (48–60) and penetratin reveal peptide induced reduction in gene expression and induction of innate immunity. Bioconjug Chem. 2007;18:1450–1459.
   PubMed Web of Science ®Google Scholar
• Lundberg P, El-Andaloussi S, Sutlu T, et al. Delivery of short interfering RNA using endosomolytic cell-penetrating peptides. Faseb J. 2007;21:2664–2671.
   PubMed Web of Science ®Google Scholar
• Deshayes S, Morris M, Heitz F, et al. Delivery of proteins and nucleic acids using a non-covalent peptide-based strategy. Adv Drug Deliv Rev. 2008;60:537–547.
   PubMed Web of Science ®Google Scholar
• Zielinski J, Kilk K, Peritz T, et al. In vivo identification of ribonucleoprotein-RNA interactions. Proc Nat Acad Sci. 2006;103:1557–1562.
   PubMed Web of Science ®Google Scholar
• Gomez JA, Gama V, Yoshida T, et al. Bax-inhibiting peptides derived from Ku70 and cell-penetrating pentapeptides. Biochem Soc Trans. 2007;35:797–801.
   PubMed Web of Science ®Google Scholar
• Han K, Jeon MJ, Kim KA, et al. Efficient intracellular delivery of GFP by homeodomains of Drosophila Fushi-tarazu and engrailed proteins. Mol Cells. 2000;10:728–732.
   PubMed Web of Science ®Google Scholar
• Kim HY, Yum SY, Jang G, et al. Discovery of a non-cationic cell penetrating peptide derived from membrane-interacting human proteins and its potential as a protein delivery carrier. Sci Rep. 2015;5:11719.
   PubMed Web of Science ®Google Scholar
• Milletti F. Cell-penetrating peptides: classes, origin, and current landscape. Drug Discov Today. 2012;17:850–860.
   PubMed Web of Science ®Google Scholar
• Farkhani SM, Valizadeh A, Karami H, et al. Cell penetrating peptides: efficient vectors for delivery of nanoparticles, nanocarriers, therapeutic and diagnostic molecules. Peptides. 2014;57:78–94.
   PubMed Web of Science ®Google Scholar
• Prochiantz A. Getting hydrophilic compounds into cells: lessons from homeopeptides. Curr Opin Neurobiol. 1999;6:629–634.
   Google Scholar
• Ragin AD, Morgan RA, Chmielewski J. Cellular import mediated by nuclear localization signal peptide sequences. Chem Biol. 2002;9:943–948.
   PubMed Web of Science ®Google Scholar
• Wang F, Wang Y, Zhang X, et al. Recent progress of cell-penetrating peptides as new carriers for intracellular cargo delivery. J Control Release. 2014;174:126–136.
   PubMed Web of Science ®Google Scholar
• Gomez JA, Chen J, Ngo J, et al. Cell-penetrating penta-peptides (CPP5s): measurement of cell entry and protein-transduction activity. Pharmaceuticals. 2010;3:3594–3613.
   Google Scholar
• Copolovici DM, Langel K, Eriste E, et al. Cell-penetrating peptides: design, synthesis, and applications. ACS Nano. 2014;8:1972–1994.
   PubMed Web of Science ®Google Scholar
• Munyendo WL, Lv H, Benza-Ingoula H, et al. Cell penetrating peptides in the delivery of biopharmaceuticals. Biomolecules. 2012;2:187–202.
   PubMedGoogle Scholar
• Gros E, Deshayes S, Morris MC, et al. A non-covalent peptide-based strategy for protein and peptide nucleic acid transduction. Biochim Biophys Acta. 2006;1758:384–393.
   PubMed Web of Science ®Google Scholar
• Zhang D, Wang J, Xu D. Cell-penetrating peptides as noninvasive transmembrane vectors for the development of novel multifunctional drug delivery systems. J Control Release. 2016;229:130–139.
   PubMed Web of Science ®Google Scholar
• Futaki S. Membrane-permeable arginine-rich peptides and the translocation mechanisms. Adv Drug Deliv Rev. 2005;57:547–558.
   PubMed Web of Science ®Google Scholar
• Amand HL, Fant K, Nordén B, et al. Stimulated endocytosis in penetratin uptake: effect of arginine and lysine. Biochem Biophys Res Commun. 2008;371:621–625.
   PubMed Web of Science ®Google Scholar
• Wang YH, Chen CP, Chan MH, et al. Arginine-rich intracellular delivery peptides noncovalently transport protein into living cells. Biochem Biophys Res Commun. 2006;346:758–767.
   PubMed Web of Science ®Google Scholar
• Mahlapuu M, Håkansson J, Ringstad L, et al. Antimicrobial peptides: an emerging category of therapeutic agents. Front Cell Infect Microbiol. 2016;6:194.
   PubMed Web of Science ®Google Scholar
• Splith K, Neundorf I. Antimicrobial peptides with cell-penetrating peptide properties and vice versa. Eur Biophys J. 2011;40(4):387–397.
   PubMed Web of Science ®Google Scholar
• Henriques ST, Melo MN, Castanho MARB. Cell-penetrating peptides and antimicrobial peptides: how different are they?. Biochem J. 2006;399(1):1–7.
   PubMedGoogle Scholar
• Mizejewski GJ. Cell-penetrating versus antimicrobial peptides: comparison of potential use as cancer therapeutics. J Oncol Res Forecast. 2019;2(1):1013.
   Google Scholar
• Rodriguez Plaza JG, Morales-Nava R, Diener C, et al. Cell penetrating peptides and cationic antibacterial peptides: two sides of the same coin. J Biol Chem. 2014;289(21):14448–14457.
   PubMed Web of Science ®Google Scholar
• Fischer R, Fotin-Mleczek M, Hufnagel H, et al. Break on through to the other side-biophysics and cell biology shed light on cell-penetrating peptides. Chembiochem. 2005;6:2126–2142.
   PubMed Web of Science ®Google Scholar
• Bechara C, Sagan S. Cell penetrating peptides: 20 years later, where do we stand? FEBS Lett. 2013;587:1693–1702.
   PubMed Web of Science ®Google Scholar
• Ye J, Fox SA, Cudic M, et al. Determination of penetratin secondary structure in live cells with Raman microscopy. J Am Chem Soc. 2009;132:980–988.
   Web of Science ®Google Scholar
• Jobin ML, Blanchet M, Henry S, et al. The role of tryptophans on the cellular uptake and membrane interaction of arginine-rich cell penetrating peptides. B.B.A. 2015;1848:593–602.
   Google Scholar
• Bechara C, Pallerla M, Zaltsman Y, et al. Tryptophan within basic peptide sequences triggers glycosaminoglycan-dependent endocytosis. Faseb J. 2013;27:738–749.
   PubMed Web of Science ®Google Scholar
• Mahajan A, Rawat AS, Bhatt N, et al. Structural modification of proteins and peptides. Indian J Pharm Educ Res. 2014;48:34–47.
   Web of Science ®Google Scholar
• Buckley ST, Hubalek F, Rahbek UL. Chemically modified peptides and proteins: critical considerations for oral delivery. Tissue Barriers. 2016;4(2):e1156805.
   PubMed Web of Science ®Google Scholar
• Lim SH, Sun Y, Madanagopal TT, et al. Enhanced skin permeation of anti-wrinkle peptides via molecular modification. Sci Rep. 2018;8:1596.
   PubMed Web of Science ®Google Scholar
• Song J, Qian Z, Sahni A, et al. Cyclic cell-penetrating peptides with single hydrophobic groups. Chembiochem. 2019;20(16):2085–2088.
   PubMed Web of Science ®Google Scholar
• Bechara C, Pallerla M, Zaltsman Y, et al. Tryptophan within basic peptide sequences triggers glycosaminoglycan-dependent endocytosis. Faseb J. 2013;27:1–12.
   PubMed Web of Science ®Google Scholar
• Walrant A, Bauzá A, Girardet C, et al. Ionpair-π interactions favor cell penetration of arginine/tryptophan-rich cell-penetrating peptides. CSH laboratory. bioRxiv. 2019. doi: 10.1101/717207.
   Google Scholar
• Bolhassani A. Potential efficacy of cell-penetrating peptides for nucleic acid and drug delivery in cancer. Biochim Biophys Acta. 2011;1816:232–246.
   PubMed Web of Science ®Google Scholar
• Madani F, Lindberg S, Langel Ü, et al. Mechanisms of cellular uptake of cell-penetrating peptides. J Biophys. 2011;2011:414729.
   PubMedGoogle Scholar
• Rothbard JB, Jessop TC, Wender PA. Adaptive translocation: the role of hydrogen bonding and membrane potential in the uptake of guanidinium-rich transporters into cells. Adv Drug Deliv Rev. 2005;57:495–504.
   PubMed Web of Science ®Google Scholar
• Derossi D, Chassaing G, Prochiantz A. Trojan peptides: the penetratin system for intracellular delivery. Trends Cell Biol. 1998;8:84–87.
   PubMed Web of Science ®Google Scholar
• Raucher D, Ryu JS. Cell-penetrating peptides: strategies for anticancer treatment. Trends Mol Med. 2015;21:560–570.
   PubMed Web of Science ®Google Scholar
• Choi YS, David AE. Cell penetrating peptides and the mechanisms for intracellular entry. Curr Pharm Biotechnol. 2014;15:192–199.
   PubMed Web of Science ®Google Scholar
• Wadia JS, Stan RV, Dowdy SF. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat Med. 2004;10:310.
   PubMed Web of Science ®Google Scholar
• Lundin P, Johansson H, Guterstam P, et al. Distinct uptake routes of cell-penetrating peptide conjugates. Bioconjug Chem. 2008;19:2535–2542.
   PubMed Web of Science ®Google Scholar
• Fonseca SB, Pereira MP, Kelley SO. Recent advances in the use of cell-penetrating peptides for medical and biological applications. Adv Drug Deliv Rev. 2009;61:953–964.
   PubMed Web of Science ®Google Scholar
• Säälik P, Elmquist A, Hansen M, et al. Protein cargo delivery properties of cell-penetrating peptides. A comparative study. Bioconjug Chem. 2004;15:1246–1253.
   PubMed Web of Science ®Google Scholar
• Futaki S, Nakase I. Cell-surface interactions on arginine-rich cell-penetrating peptides allow for multiplex modes of internalization. Acc Chem Res. 2017;50:2449–2456.
   PubMed Web of Science ®Google Scholar
• Wagstaff KM, Jans DA. Protein transduction: cell penetrating peptides and their therapeutic applications. Curr Med Chem. 2006;13:1371–1387.
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Futaki S. Current understanding of direct translocation of arginine-rich cell-penetrating peptides and its internalization mechanisms. Chem Pharm Bull. 2016;64(10):1431–1437.
   PubMed Web of Science ®Google Scholar
• Langel U. CPP: cell penetrating peptides, Google books result. Science. 2019;361.
   Google Scholar
• Meloni BP, Milani D, Edwards AB, et al. Neuroprotective peptides fused to arginine-rich cell penetrating peptides: neuroprotective mechanism likely mediated by peptide endocytic properties. Pharmacol Ther. 2015;153:36–54.
   PubMed Web of Science ®Google Scholar
• Nakase I, Noguchi K, Aoki A, et al. Arginine-rich cell-penetrating peptide-modified extracellular vesicles for active macropinocytosis induction and efficient intracellular delivery. Sci Rep. 2017;7:1991.
   PubMed Web of Science ®Google Scholar
• Freimann K, Arukuusk P, Kurrikoff K, et al. Optimization of in vivo DNA delivery with NickFect peptide vectors. J Control Release. 2016;241:135–143.
   PubMed Web of Science ®Google Scholar
• Wang H, Zhong CY, Wu JF, et al. Enhancement of TAT cell membrane penetration efficiency by dimethyl sulphoxide. J Control Release. 2010;143:64–70.
   PubMed Web of Science ®Google Scholar
• Abes S, Williams D, Prevot P, et al. Endosome trapping limits the efficiency of splicing correction by PNA-oligolysine conjugates. J Control Release. 2006;110(3):595–604.
   PubMed Web of Science ®Google Scholar
• Wang H, Zhang M, Zeng F, et al. Hyperosmotic treatment synergistically boosts efficiency of cell-permeable peptides. Oncotarget. 2016;7(46):74648–74657.
   PubMedGoogle Scholar
• Layek B, Lipp L, Singh J. Cell penetrating peptide conjugated chitosan for enhanced delivery of nucleic acid. Int J Mol Sci. 2015;16:28912–28930.
   PubMed Web of Science ®Google Scholar
• Rahmat D, Khan MI, Shahnaz G, et al. Synergistic effects of conjugating cell penetrating peptides and thiomers on non-viral transfection efficiency. Biomaterials. 2012;33:2321–2326.
   PubMed Web of Science ®Google Scholar
• Shiraishi T, Nielsen PE. Enhanced delivery of cell-penetrating peptide-peptide nucleic acid conjugates by endosomal disruption. Nat Protoc. 2006;1:633.
   PubMed Web of Science ®Google Scholar
• Mohammed AF, Abdul-Wahid A, Huang EH, et al. The pseudomonas aeruginosa exotoxin A translocation domain facilitates the routing of CPP-protein cargos to the cytosol of eukaryotic cells. J Control Release. 2012;164:58–64.
   PubMed Web of Science ®Google Scholar
• Zhang P, Monteiro Da Silva G, Deatherage C, et al. Cell-penetrating peptide mediates intracellular membrane passage of human papillomavirus L2 protein to trigger retrograde trafficking. Cell. 2018;174:1465–1476.
   PubMed Web of Science ®Google Scholar
• Lee SH, Leroux JC. Is there a future for cell-penetrating peptides in oligonucleotide delivery? Eur J Pharm Biopharm. 2013;85:5–11.
   PubMed Web of Science ®Google Scholar
• Rizzuti M, Zanetta C, Ramirez A, et al. Therapeutic applications of the cell-penetrating HIV-1 Tat peptide. Drug Discov Today. 2015;20:76–85.
   PubMed Web of Science ®Google Scholar
• Foged C. Cell-penetrating peptides for drug delivery across membrane barriers. Expert Opin Drug Deliv. 2008;5:105–117.
   PubMed Web of Science ®Google Scholar
• El-Andaloussi S, Johansson HJ, Langel Ü. Cargo-dependent cytotoxicity and delivery efficacy of cell-penetrating peptides: a comparative study. Biochem J. 2007;407:285–292.
   PubMed Web of Science ®Google Scholar
• Berry CC. Intracellular delivery of nanoparticles via the HIV-1 tat peptide. Nanomedicine. 2008;3:357–365.
   PubMed Web of Science ®Google Scholar
• Astriab-Fisher A, Fisher M, Shaw BR, et al. Conjugates of antisense oligonucleotides with the Tat and antennapedia cell-penetrating peptides: effects on cellular uptake, binding to target sequences, and biologic actions. Pharm Res. 2002;19:744–754.
   PubMed Web of Science ®Google Scholar
• Akkarawongsa R, Cullinan AE, Zinkel A, et al. Corneal toxicity of cell-penetrating peptides that inhibit herpes simplex virus entry. J Ocul Pharmacol Ther. 2006;22:279–289.
   PubMed Web of Science ®Google Scholar
• Vives E, Brodin P, Lebleu B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem. 1997;272:16010–16017.
   PubMed Web of Science ®Google Scholar
• Harbour JW, Worley L, Ma D, et al. Transducible peptide therapy for uveal melanoma and retinoblastoma. Arch Ophthalmol. 2002;120:1341–1346.
   PubMed Web of Science ®Google Scholar
• Pescina S, Ostacolo C, Gomez-Monterrey IM, et al. Cell penetrating peptides in ocular drug delivery: state of the art. J Control Release. 2018;284:84–102.
   PubMed Web of Science ®Google Scholar
• Lindgren M, Rosenthal-Aizman K, Saar K, et al. Overcoming methotrexate resistance in breast cancer tumour cells by the use of a new cell-penetrating peptide. Biochem Pharmacol. 2006;71:416–425.
   PubMed Web of Science ®Google Scholar
• Park N, Yamanaka K, Tran D, et al. The cell-penetrating peptide, Pep-1, has activity against intracellular chlamydial growth but not extracellular forms of chlamydia trachomatis. J Antimicrob Chemother. 2008;63:115–123.
   PubMed Web of Science ®Google Scholar
• El-Andaloussi S, Johansson HJ, Holm T, et al. A novel cell-penetrating peptide, M918, for efficient delivery of proteins and peptide nucleic acids. Mol Ther. 2007;15:1820–1826.
   PubMed Web of Science ®Google Scholar
• Holm T, Räägel H, Andaloussi SE, et al. Retro-inversion of certain cell-penetrating peptides causes severe cellular toxicity. B.B.A. 2011;1808:1544–1551.
   Google Scholar
• Feni L, Neundorf I The current role of cell-penetrating peptides in cancer therapy. In: Peptides and peptide-based biomaterials and their biomedical applications. Springer; 2017. p. 279–295.
   Google Scholar
• Koren E, Apte A, Sawant RR, et al. Cell-penetrating TAT peptide in drug delivery systems: proteolytic stability requirements. Drug Deliv. 2011;18:377–384.
   PubMed Web of Science ®Google Scholar
• Mäe M, Langel U. Cell-penetrating peptides as vectors for peptide, protein and oligonucleotide delivery. Curr Opin Pharmacol. 2006;6:509–514.
   PubMed Web of Science ®Google Scholar
• Kristensen M, Birch D, Morck Nielsen H. Applications and challenges for use of cell-penetrating peptides as delivery vectors for peptide and protein cargos. Int J Mol Sci. 2016;17:E185.
   PubMed Web of Science ®Google Scholar
• Schwarze SR, Ho A, Vocero-Akbani A, et al. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science. 1999;285:1569–1572.
   PubMed Web of Science ®Google Scholar
• Cao G, Pei W, Ge H, et al. In vivo delivery of a Bcl-xL fusion protein containing the TAT protein transduction domain protects against ischemic brain injury and neuronal apoptosis. J Neurosci. 2002;22:5423–5431.
   PubMed Web of Science ®Google Scholar
• Kim D, Kim CH, Moon JI, et al. Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell. 2009;4:472–476.
   PubMed Web of Science ®Google Scholar
• Jones SW, Christison R, Bundell K, et al. Characterisation of cell-penetrating peptide-mediated peptide delivery. Br J Pharmacol. 2005;145:1093–1102.
   PubMed Web of Science ®Google Scholar
• Wang H, Ma JL, Yang YG, et al. Efficient therapeutic delivery by a novel cell-permeant peptide derived from KDM4A protein for antitumor and antifibrosis. Oncotarget. 2016;7(31):1–16.
   PubMedGoogle Scholar
• Shahbazi S, Haghighipour N, Soleymani S, et al. Delivery of molecular cargoes in normal and cancer cell lines using non-viral delivery systems. Biotechnol Lett. 2018;40:923–931.
   PubMed Web of Science ®Google Scholar
• Ding Y, Zhao X, Geng J, et al. Intracellular delivery of nucleic acid by cell-permeable hPP10 peptide. J Cell Physiol. 2019;234(7):11670–11678.
   PubMed Web of Science ®Google Scholar
• Wang H, Ma J, Yang Y, et al. Highly efficient delivery of functional cargoes by a novel cell-penetrating peptide derived from SP140-like protein. Bioconjug Chem. 2016;27(5):1373–1381.
   PubMed Web of Science ®Google Scholar
• Kwon HK, Patra MC, Shin HJ, et al. A cell-penetrating peptide blocks Toll-like receptor-mediated downstream signaling and ameliorates autoimmune and inflammatory diseases in mice. Exp Mol Med. 2019;51:50.
   PubMed Web of Science ®Google Scholar
• Morris MC, Depollier J, Mery J, et al. A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat Biotechnol. 2001;19:1173–1176.
   PubMed Web of Science ®Google Scholar
• Kurzawa L, Pellerano M, Morris MC. PEP and CADY-mediated delivery of fluorescent peptides and proteins into living cells. Biochim Biophys Acta. 2010;1798:2274–2285.
   PubMed Web of Science ®Google Scholar
• Rostami B, Irani S, Bolhassani A, et al. M918: a novel cell penetrating peptide for effective delivery of HIV-1 Nef and Hsp20-Nef proteins into eukaryotic cell lines. Curr HIV Res. 2018;16:280–287.
   PubMed Web of Science ®Google Scholar
• Kamei N, Nielsen EJ, Khafagy el S, et al. Non-invasive insulin delivery: the great potential of cell-penetrating peptides. Ther Deliv. 2013;4:315–326.
   PubMedGoogle Scholar
• Ponnappan N, Budagavi DP, Chugh A. CyLoP-1: membrane-active peptide with cell-penetrating and antimicrobial properties. Biochimica Et Biophysica Acta Biomembranes. 2017;1859:167–176.
   PubMed Web of Science ®Google Scholar
• Ponnappan N, Chugh A. Cell-penetrating and cargo-delivery ability of a spider toxin-derived peptide in mammalian cells. Eur J Pharm Biopharm. 2017;114:145–153.
   PubMed Web of Science ®Google Scholar
• Salerno JC, Ngwa VM, Nowak SJ, et al. Novel cell-penetrating peptide-adaptors effect intracellular delivery and endosomal escape of protein cargos. J Cell Sci. 2016;129:2473–2474.
   PubMed Web of Science ®Google Scholar
• Akdag IO, Ozkirimli E. The uptake mechanism of the cell-penetrating pVEC peptide. J Chem. 2013;2013:1–9.
   Google Scholar
• Elmquist A, Hansen M, Langel Ü. Structure-activity relationship study of the cell-penetrating peptide pVEC. B.B.A. 2006;1758:721–729.
   Google Scholar
• Jo D, Liu D, Yao S, et al. Intracellular protein therapy with SOCS3 inhibits inflammation and apoptosis. Nat Med. 2005;11:892.
   PubMed Web of Science ®Google Scholar
• Bleifuss E, Kammertoens T, Hutloff A, et al. The translocation motif of hepatitis B virus improves protein vaccination. Cell Mol Life Sci. 2006;63:627.
   PubMed Web of Science ®Google Scholar
• Park JH, Lee JH, Park HH, et al. A protein delivery system using 30Kc19 cell-penetrating protein originating from silkworm. Biomaterials. 2012;33:9127–9134.
   PubMed Web of Science ®Google Scholar
• Im J, Das S, Jeong D, et al. Intracellular and transdermal protein delivery mediated by non-covalent interactions with a synthetic guanidine-rich molecular carrier. Int J Pharm. 2017;528:646–654.
   PubMed Web of Science ®Google Scholar
• Gautam A, Nanda JS, Samuel JS, et al. Topical delivery of protein and peptide using novel cell penetrating peptide IMT-P8. Sci Rep. 2016;6:26278.
   PubMed Web of Science ®Google Scholar
• Koo JH, Yoon H, Kim WJ, et al. Cell penetrating function of the poly (ADP-Ribose)(PAR)-binding motif derived from the PAR-dependent E3 ubiquitin ligase iduna. Int J Mol Sci. 2018;19:779.
   Web of Science ®Google Scholar
• Aoshiba K, Yokohori N, Nagai A. Alveolar wall apoptosis causes lung destruction and emphysematous changes. Am J Respir Cell Mol Biol. 2003;28:555–562.
   PubMed Web of Science ®Google Scholar
• Rawe VY, Payne C, Navara C, et al. WAVE1 intranuclear trafficking is essential for genomic and cytoskeletal dynamics during fertilization: cell-cycle-dependent shuttling between M-phase and interphase nuclei. Dev Biol. 2004;276:253–267.
   PubMed Web of Science ®Google Scholar
• Michiue H, Tomizawa K, Wei FY, et al. The NH2 terminus of influenza virus hemagglutinin-2 subunit peptides enhances the antitumor potency of polyarginine-mediated p53 protein transduction. J Biol Chem. 2005;280:8285–8289.
   PubMed Web of Science ®Google Scholar
• Trabulo S, Cardoso AL, Mano M, et al. Cell penetrating peptides mechanisms of cellular uptake and generation of delivery systems. Pharmaceuticals (Basel). 2010;3:961–993.
   PubMedGoogle Scholar
• Fang B, Jiang L, Zhang M, et al. A novel cell-penetrating peptide TAT-A1 delivers siRNA into tumor cells selectively. Biochimie. 2013;95:251–257.
   PubMed Web of Science ®Google Scholar
• Kim WJ, Christensen LV, Jo S, et al. Cholesteryl oligoarginine delivering vascular endothelial growth factor siRNA effectively inhibits tumor growth in colon adenocarcinoma. Mol Ther. 2006;14:343–350.
   PubMed Web of Science ®Google Scholar
• Kumar P, Wu H, McBride JL, et al. Transvascular delivery of small interfering RNA to the central nervous system. Nature. 2007;448:39–43.
   PubMed Web of Science ®Google Scholar
• Eguchi A, Dowdy SF. Efficient siRNA delivery by novel PTD-DRBD fusion proteins. Cell Cycle. 2010;9:424–425.
   PubMed Web of Science ®Google Scholar
• Eguchi A, Meade BR, Chang YC, et al. Efficient siRNA delivery into primary cells by a peptide transduction domain-dsRNA binding domain fusion protein. Nat Biotechnol. 2009;27:567–571.
   PubMed Web of Science ®Google Scholar
• Simeoni F, Morris MC, Heitz F, et al. Insight into the mechanism of the peptide-based gene delivery system MPG: implications for delivery of siRNA into mammalian cells. Nucleic Acids Res. 2003;31:2717–2724.
   PubMed Web of Science ®Google Scholar
• Lehto T, Kurrikoff K, Langel Ü. Cell-penetrating peptides for the delivery of nucleic acids. Expert Opin Drug Deliv. 2012;9:823–836.
   PubMed Web of Science ®Google Scholar
• Cheng CJ, Saltzman WM. Enhanced siRNA delivery into cells by exploiting the synergy between targeting ligands and cell-penetrating peptides. Biomaterials. 2011;32:6194–6203.
   PubMed Web of Science ®Google Scholar
• Nakase I, Tanaka G, Futaki S. Cell-penetrating peptides (CPPs) as a vector for the delivery of siRNAs into cells. Mol Biosyst. 2013;9:855–861.
   PubMed Web of Science ®Google Scholar
• Pan R, Xu W, Ding Y, et al. Uptake mechanism and direct translocation of a Nnew CPP for siRNA delivery. Mol Pharm. 2016;13:1366–1374.
   PubMed Web of Science ®Google Scholar
• Danielson DC, Sachrajda N, Wang W, et al. A novel p19 fusion protein as a delivery agent for short-interfering RNAs. Mol Ther Nucleic Acids. 2016;5:e303.
   PubMedGoogle Scholar
• Welch JJ, Swanekamp RJ, King C, et al. Functional delivery of siRNA by disulfide-constrained cyclic amphipathic peptides. ACS Med Chem Lett. 2016;7:584–589.
   PubMed Web of Science ®Google Scholar
• Vaissière A, Aldrian G, Konate K, et al. A retro‑inverso cell penetrating peptide for siRNA delivery. J Nanobiotechnol. 2017;15:34.
   PubMed Web of Science ®Google Scholar
• Aldrian G, Vaissière A, Konate K, et al. PEGylation rate influences peptide-based nanoparticles mediated siRNA delivery in vitro and in vivo. J Control Release. 2017;256:79–91.
   PubMed Web of Science ®Google Scholar
• Konate K, Dussot M, Aldrian G, et al. Peptide-based nanoparticles to rapidly and efficiently “Wrap’n Roll” siRNA into cells. Bioconjug Chem. 2019;30(3):592–603.
   PubMed Web of Science ®Google Scholar
• Kadkhodayan S, Bolhassani A, Sadat SM, et al. The efficiency of Tat cell penetrating peptide for intracellular uptake of HIV-1 Nef expressed in E. coli and mammalian cell. Curr Drug Deliv. 2017;14:536–542.
   PubMed Web of Science ®Google Scholar
• Hyndman L, Lemoine JL, Huang L, et al. HIV-1 Tat protein transduction domain peptide facilitates gene transfer in combination with cationic liposomes. J Control Release. 2004;99:435–444.
   PubMed Web of Science ®Google Scholar
• Morris MC, Chaloin L, Mery J, et al. A novel potent strategy for gene delivery using a single peptide vector as a carrier. Nucleic Acids Res. 1999;27:3510–3517.
   PubMed Web of Science ®Google Scholar
• Saleh T, Bolhassani A, Shojaosadati SA, et al. Evaluation of cell penetrating peptide delivery system on HPV16 E7 expression in three types of cell line. Iran J Biotechnol. 2015;13:55–62.
   PubMed Web of Science ®Google Scholar
• Rittner K, Benavente A, Bompard-Sorlet A, et al. New basic membrane-destabilizing peptides for plasmid-based gene delivery in vitro and in vivo. Mol Ther. 2002;5:104–114.
   PubMed Web of Science ®Google Scholar
• Gupta B, Levchenko TS, Torchilin VP. Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. Adv Drug Deliv Rev. 2005;57:637–651.
   PubMed Web of Science ®Google Scholar
• Veiman KL, Mager I, Ezzat K, et al. PepFect14 peptide vector for efficient gene delivery in cell cultures. Mol Pharm. 2013;10:199–210.
   PubMed Web of Science ®Google Scholar
• Liu BR, Liou JS, Chen YJ, et al. Delivery of nucleic acids, proteins, and nanoparticles by arginine-rich cell-penetrating peptides in rotifers. Mar Biotechnol. 2013;15:584–595.
   PubMed Web of Science ®Google Scholar
• Lehto T, Simonson OE, Mager I, et al. A peptide-based vector for efficient gene transfer in vitro and in vivo. Mol Ther. 2011;19:1457–1467.
   PubMed Web of Science ®Google Scholar
• Freimann K, Arukuusk P, Kurrikoff K, et al. Formulation of stable and homogeneous cell-penetrating peptide NF55 nanoparticles for efficient gene delivery in vivo. Mol Ther Nucleic Acids. 2018;10:28–35.
   PubMedGoogle Scholar
• Jeong C, Yoo J, Lee D, et al. A branched TAT cell-penetrating peptide as a novel delivery carrier for the efficient gene transfection. Biomater Res. 2016;20:28.
   PubMedGoogle Scholar
• Saleh AF, Aojula H, Arthanari Y, et al. Improved Tat-mediated plasmid DNA transfer by fusion to LK15 peptide. J Control Release. 2010;143:233–242.
   PubMed Web of Science ®Google Scholar
• Yoo J, Lee D, Gujrati V, et al. Bioreducible branched poly(modified nona-arginine) cell-penetrating peptide as a novel gene delivery platform. J Control Release. 2017;246:142–154.
   PubMed Web of Science ®Google Scholar
• Pooga M, Soomets U, Hällbrink M, et al. Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo. Nat Biotechnol. 1998;16:857.
   PubMed Web of Science ®Google Scholar
• Abes S, Turner JJ, Ivanova GD, et al. Efficient splicing correction by PNA conjugation to an R6-Penetratin delivery peptide. Nucleic Acids Res. 2007;35:4495–4502.
   PubMed Web of Science ®Google Scholar
• Zavaglia D, Normand N, Brewis N, et al. VP22-mediated and light-activated delivery of an anti-c-raf1 antisense oligonucleotide improves its activity after intratumoral injection in nude mice. Mol Ther. 2003;8:840–845.
   PubMed Web of Science ®Google Scholar
• Ramakrishna S, Kwaku Dad AB, Beloor J, et al. Gene disruption by cell-penetrating peptide-mediated delivery of Cas9 protein and guide RNA. Genome Res. 2014;24:1020–1027.
   PubMed Web of Science ®Google Scholar
• He Y, Li F, Huang Y. Smart cell-penetrating peptide-based techniques for intracellular delivery of therapeutic macromolecules. Adv Protein Chem Struct Biol. 2018;112:183–220.
   PubMed Web of Science ®Google Scholar
• Torchilin VP. Cell penetrating peptide-modified pharmaceutical nanocarriers for intracellular drug and gene delivery. Pept Sci. 2008;90:604–610.
   Google Scholar
• Dissanayake S, Denny WA, Gamage S, et al. Recent developments in anticancer drug delivery using cell penetrating and tumor targeting peptides. J Control Release. 2017;250:62–76.
   PubMed Web of Science ®Google Scholar
• Gan BK, Ho KL, Omar AR, et al. Targeted delivery of cell penetrating peptide virus-like nanoparticles to skin cancer cells. Sci Rep. 2018;8:8499.
   PubMedGoogle Scholar
• Kumar V, Kumar R, Bhalla S, et al. Prediction of cell-penetrating potential of modified peptides containing natural and chemically modified residues. Front Microbiol. 2018;9:725.
   PubMed Web of Science ®Google Scholar
• Chugh A, Eudes F, Shim YS. Cell penetrating peptides: nanocarrier for macromolecule delivery in living cells. IUBMB Life. 2010;62:183–193.
   PubMed Web of Science ®Google Scholar
• Sarko D, Beijer B, Garcia Boy R, et al. The pharmacokinetics of cell-penetrating peptides. Mol Pharm. 2010;7:2224–2231.
   PubMed Web of Science ®Google Scholar
• Morris MC, Chaloin L, Heitz F, et al. Translocating peptides and proteins and their use for gene delivery. Curr Opin Biotechnol. 2000;11:461–466.
   PubMed Web of Science ®Google Scholar
• Zhong J, Zhu X, Guan S, et al. A smart polymeric platform for multistage nucleus-targeted anticancer drug delivery. Biomaterials. 2015;65:43–55.
   PubMed Web of Science ®Google Scholar
• Lindgren M, Prochiantz A, Langel Ü. Cell-penetrating peptides. Trends Pharmacol Sci. 2000;21:99–103.
   PubMed Web of Science ®Google Scholar
• Tung CH, Mueller S, Weissleder R. Novel branching membrane translocational peptide as gene delivery vector. Bioorg Med Chem. 2002;10:3609–3614.
   PubMed Web of Science ®Google Scholar
• Torchilin VP. Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers. Adv Drug Deliv Rev. 2008;60:548–558.
   PubMed Web of Science ®Google Scholar
• Temsamani J. The use of cell-penetrating peptides for drug delivery. Drug Discov Today. 2004;9:1012–1019.
   PubMed Web of Science ®Google Scholar
• Gorodetsky R, Levdansky L, Vexler A, et al. Liposome transduction into cells enhanced by haptotactic peptides (Haptides) homologous to fibrinogen C-termini. J Control Release. 2004;95:477–488.
   PubMed Web of Science ®Google Scholar
• Gorodetsky R, Vexler A, Shamir M, et al. New cell attachment peptide sequences from conserved epitopes in the carboxy termini of fibrinogen. Exp Cell Res. 2003;287:116–129.
   PubMed Web of Science ®Google Scholar
• El-Sayed NS, Shirazi A, Park S, et al. Design, synthesis, and evaluation of homochiral peptides containing arginine and histidine as molecular transporters. Molecules. 2018;23:1590.
   Web of Science ®Google Scholar
• Weinstain R, Savariar EN, Felsen CN, et al. In vivo targeting of hydrogen peroxide by activatable cell-penetrating peptides. J Am Chem Soc. 2014;136:874–877.
   PubMed Web of Science ®Google Scholar
• Lee SH, Castagner B, Leroux JC. Activatable cell penetrating peptide-peptide nucleic acid conjugate via reduction of azobenzene PEG chains. J Am Chem Soc. 2014;136:12868–12871.
   PubMed Web of Science ®Google Scholar
• Chen S, Cui J, Jiang T, et al. Gelatinase activity imaged by activatable cell-penetrating peptides in cell-based and in vivo models of stroke. J Cereb Blood Flow Metab. 2017;37:188–200.
   PubMed Web of Science ®Google Scholar
• Shi NQ, Gao W, Xiang B, et al. Enhancing cellular uptake of activable cell-penetrating peptide-doxorubicin conjugate by enzymatic cleavage. Int J Nanomedicine. 2012;7:1613–1621.
   PubMed Web of Science ®Google Scholar
• Sawant RM, Salmaso S, Kale A, et al. SMART” drug delivery systems: double-targeted pH-responsive pharmaceutical nanocarriers. Bioconjug Chem. 2006;17:943–949.
   PubMed Web of Science ®Google Scholar
• Kale AA, Torchilin VP. Enhanced transfection of tumor cells in vivo using “Smart” pH-sensitive TAT-modified pegylated liposomes. J Drug Target. 2007;15:538–545.
   PubMed Web of Science ®Google Scholar
• Kale AA, Torchilin VP. Design, synthesis, and characterization of pH-sensitive PEG-PE conjugates for stimuli-sensitive pharmaceutical nanocarriers: the effect of substitutes at the hydrazone linkage on the pH stability of PEG-PE conjugates. Bioconjug Chem. 2007;18:363–370.
   PubMed Web of Science ®Google Scholar
• Suk JS, Xu Q, Kim N, et al. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev. 2016;99:28–51.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Fu L, Ran R, et al. A pH-responsive α-helical cell penetrating peptide-mediated liposomal delivery system. Biomaterials. 2013;34:7980–7993.
   PubMed Web of Science ®Google Scholar
• Tu Z, Volk M, Shah K, et al. Constructing bioactive peptides with pH-dependent activities. Peptides. 2009;30:1523–1528.
   PubMed Web of Science ®Google Scholar
• Zhang W, Song J, Zhang B, et al. Design of acid-activated cell penetrating peptide for delivery of active molecules into cancer cells. Bioconjug Chem. 2011;22:1410–1415.
   PubMed Web of Science ®Google Scholar
• Jiang T, Zhang Z, Zhang Y, et al. Dual-functional liposomes based on pH-responsive cell-penetrating peptide and hyaluronic acid for tumor-targeted anticancer drug delivery. Biomaterials. 2012;33:9246–9258.
   PubMed Web of Science ®Google Scholar
• Walker L, Perkins E, Kratz F, et al. Cell penetrating peptides fused to a thermally targeted biopolymer drug carrier improve the delivery and antitumor efficacy of an acid-sensitive doxorubicin derivative. Int J Pharm. 2012;436:825–832.
   PubMed Web of Science ®Google Scholar
• He H, Ye J, Wang Y, et al. Cell-penetrating peptides meditated encapsulation of protein therapeutics into intact red blood cells and its application. J Control Release. 2014;176:123–132.
   PubMed Web of Science ®Google Scholar
• Wender PA, Galliher WC, Bhat NM, et al. Taxol-oligoarginine conjugates overcome drug resistance in-vitro in human ovarian carcinoma. Gynecol Oncol. 2012;126:118–123.
   PubMed Web of Science ®Google Scholar
• Horton KL, Fonseca SB, Guo Q, et al. Mitochondria-penetrating peptides. Chem Biol. 2008;15:375–382.
   PubMed Web of Science ®Google Scholar
• Cross RL, Müller V. The evolution of A-, F-, and V-type ATP synthases and ATPases: reversals in function and changes in the H+/ATP coupling ratio. FEBS Lett. 2004;576:1–4.
   PubMed Web of Science ®Google Scholar
• Rappas M, Niwa H, Zhang X. Mechanisms of ATPases-A multi-disciplinary approach. Curr Protein Pept Sci. 2004;5:89–105.
   PubMed Web of Science ®Google Scholar
• Radis-Baptista G, Campelo IS, Morlighem JRL, et al. Cell-penetrating peptides (CPPs): from delivery of nucleic acids and antigens to transduction of engineered nucleases for application in transgenesis. J Biotechnol. 2017;252:15–26.
   PubMed Web of Science ®Google Scholar
• Brooks NA, Pouniotis DS, Tang CK, et al. Cell-penetrating peptides: application in vaccine delivery. B.B.A. 2010;1805:25–34.
   Google Scholar
• Yang J, Luo Y, Shibu MA, et al. Cell-penetrating peptides: efficient vectors for vaccine delivery. Curr Drug Deliv. 2019;16:430–443.
   PubMed Web of Science ®Google Scholar
• Mardani G, Bolhassani A, Agi E, et al. Protein vaccination with HPV16 E7/Pep-1 nanoparticles elicits a protective T-helper cell-mediated immune response. IUBMB-Life. 2016;68:459–467.
   PubMed Web of Science ®Google Scholar
• Bolhassani A, Kardani K, Vahabpour R, et al. Prime/boost immunization with HIV-1 MPER-V3 fusion construct enhances humoral and cellular immune responses. Immunol Lett. 2015;168:366–373.
   PubMed Web of Science ®Google Scholar
• Saleh T, Bolhassani A, Shojaosadati SA, et al. MPG-based nanoparticle: an efficient delivery system for enhancing the potency of DNA vaccine expressing HPV16E7. Vaccine. 2015;33:3164–3170.
   PubMed Web of Science ®Google Scholar
• Mehrlatifan S, Mirnurollahi SM, Motevalli F, et al. The structural HCV genes delivered by MPG cell penetrating peptide are directed to enhance immune responses in mice model. Drug Deliv. 2016;23:2852–2859.
   PubMed Web of Science ®Google Scholar
• Kadkhodayan S, Jafarzade BS, Sadat SM, et al. Combination of cell penetrating peptides and heterologous DNA prime/protein boost strategy enhances immune responses against HIV-1 Nef antigen in BALB/c mouse model. Immunol Lett. 2017;188:38–45.
   PubMed Web of Science ®Google Scholar
• Irvine AS, Trinder PK, Laughton DL, et al. Mountain, efficient non-viral transfection of dendritic cells and their use for in vivo immunization. Nat Biotechnol. 2000;18:1273–1278.
   PubMed Web of Science ®Google Scholar
• Shibagaki N, Udey MC. Dendritic cells transduced with protein antigens induce cytotoxic lymphocytes and elicit antitumor immunity. J Immunol. 2002;168:2393–2401.
   PubMed Web of Science ®Google Scholar
• Shibagaki N, Udey MC. Dendritic cells transduced with TAT protein transduction domain-containing tyrosinase-related protein 2 vaccinate against murine melanoma. Eur J Immunol. 2003;33:850–860.
   PubMed Web of Science ®Google Scholar
• Bolhassani A, Gholami E, Zahedifard F, et al. Leishmania major: protective capacity of DNA vaccine using amastin fused to HSV-1 VP22 and EGFP in BALB/c mice model. Exp Parasitol. 2011;128:9–17.
   PubMed Web of Science ®Google Scholar
• Kronenberg K, Brosch S, Butsch F, et al. Vaccination with TAT-antigen fusion protein induces protective, CD8＋T cell-mediated immunity against Leishmania major. J Invest Dermatol. 2010;130:2602–2610.
   PubMed Web of Science ®Google Scholar
• Justesen S, Buus S, Claesson MH, et al. Addition of TAT protein transduction domain and GrpE to human p53 provides soluble fusion proteins that can be transduced into dendritic cells and elicit p53-specific T-cell responses in HLA-A*0201 transgenic mice. Immunology. 2007;122:326–334.
   PubMed Web of Science ®Google Scholar
• Viehl CT, Becker-Hapak M, Lewis JS, et al. A Tat fusion protein-based tumor vaccine for breast cancer. Ann Surg Oncol. 2005;12:517–525.
   PubMed Web of Science ®Google Scholar
• Woo SJ, Kim CH, Park MY, et al. Co-administration of carcinoembryonic antigen and HIV TAT fusion protein with CpG-oligodeoxynucleotide induces potent antitumor immunity. Cancer Sci. 2008;99:1034–1039.
   PubMed Web of Science ®Google Scholar
• Mitsui H, Inozume T, Kitamura R, et al. Polyarginine-mediated protein delivery to dendritic cells presents antigen more efficiently onto MHC class I and class II and elicits superior antitumor immunity. J Invest Dermatol. 2006;126:1804–1812.
   PubMed Web of Science ®Google Scholar
• Pouniotis DS, Apostolopoulos V, Pietersz GA. Penetratin tandemly linked to a CTL peptide induces anti-tumour T-cell responses via a cross-presentation pathway. Immunology. 2006;117:329–339.
   PubMed Web of Science ®Google Scholar
• Apostolopoulos V, Pouniotis DS, van Maanen PJ, et al. Delivery of tumor associated antigens to antigen presenting cells using penetratin induces potent immune responses. Vaccine. 2006;24:3191–3202.
   PubMed Web of Science ®Google Scholar
• Hung CF, Cheng WF, Chai CY, et al. Improving vaccine potency through intercellular spreading and enhanced MHC class I presentation of antigen. J Immunol. 2001;166:5733–5740.
   PubMed Web of Science ®Google Scholar
• Kim TW, Hung CF, Kim JW, et al. Vaccination with a DNA vaccine encoding herpes simplex virus type 1 VP22 linked to antigen generates long-term antigen-specific CD8+ memory T cells and protective immunity. Hum Gene Ther. 2004;15:167–177.
   PubMed Web of Science ®Google Scholar
• Yu X, Wang Y, Xia Y, et al. A DNA vaccine encoding VP22 of herpes simplex virus type I (HSV-1) and OprF confers enhanced protection from Pseudomonas aeruginosa in mice. Vaccine. 2016;34:4399–4405.
   PubMed Web of Science ®Google Scholar
• Kardani K, Bolhassani A, Shahbazi S. Prime-boost vaccine strategy against viral infections: mechanisms and benefits. Vaccine. 2016;34:413–423.
   PubMed Web of Science ®Google Scholar
• Saha S, Yoshida S, Ohba K, et al. A fused gene of nucleoprotein (NP) and herpes simplex virus genes (VP22) induces highly protective immunity against different subtypes of influenza virus. Virology. 2006;354:48–57.
   PubMed Web of Science ®Google Scholar
• Grau M, Walker PR, Derouazi M. Mechanistic insights into the efficacy of cell penetrating peptide-based cancer vaccines. Cell Mol Life Sci. 2018;75:2887–2896.
   PubMed Web of Science ®Google Scholar
• Derouazi M, Di Berardino-Besson W, Belnoue E, et al. Novel cell penetrating peptide-based vaccine induces robust CD4+ and CD8+ T cell-mediated antitumor immunity. Cancer Res. 2015;75:3020–3031.
   PubMed Web of Science ®Google Scholar
• Belnoue E, Di Berardino-Besson W, Gaertner H, et al. Enhancing antitumor immune responses by optimized combinations of cell-penetrating peptide-based vaccines and adjuvants. Mol Ther. 2016;24:1675–1685.
   PubMed Web of Science ®Google Scholar
• Wang RF, Wang HY. Enhancement of antitumor immunity by prolonging antigen presentation on dendritic cells. Nat Biotechnol. 2002;20:149.
   PubMed Web of Science ®Google Scholar
• Hung CF, He L, Juang J, et al. Improving DNA vaccine potency by linking Marek’s disease virus type 1 VP22 to an antigen. J Virol. 2002;76:2676–2682.
   PubMed Web of Science ®Google Scholar
• Shahbazi S, Bolhassani A. Comparison of six cell penetrating peptides with different properties for in vitro and in vivo delivery of HPV16 E7 antigen in therapeutic vaccines. Int Immunopharmacol. 2018;62:170–180.
   PubMed Web of Science ®Google Scholar
• Mohit E, Bolhassani A, Zahedifard F, et al. Immunomodulatory effects of IP-10 chemokine along with PEI600-Tat delivery system in DNA vaccination against HPV infections. Mol Immunol. 2013;53:149–160.
   PubMed Web of Science ®Google Scholar
• Lim S, Choi JM. Use of cell penetrating peptides in dendritic cell-based vaccination. Immune Netw. 2016;16:33–43.
   PubMed Web of Science ®Google Scholar
• Dakappagari N, Sundaram R, Rawale S, et al. Intracellular delivery of a novel multiepitope peptide vaccine by an amphipathic peptide carrier enhances cytotoxic Tcell responses in HLA-A*201 mice. J Pept Res. 2005;65:189–199.
   PubMedGoogle Scholar
• Rostami B, Irani S, Bolhassani A, et al. Gene and protein delivery using four cell penetrating peptides for HIV-1 vaccine development. IUBMB Life. 2019;71(10);1619–1633.
   Web of Science ®Google Scholar
• Alizadeh S, Irani S, Bolhassani A, et al. Simultaneous use of natural adjuvants and cell penetrating peptides improves HCV NS3 antigen-specific immune responses. Immunol Lett. 2019;212:70–80.
   PubMed Web of Science ®Google Scholar
• Tashima T. Intelligent substance delivery into cells using cell-penetrating peptides. Bioorg Med Chem Lett. 2017;27:121–130.
   PubMed Web of Science ®Google Scholar
• Rousselle C, Clair P, Lefauconnier JM, et al. New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy. Mol Pharmacol. 2000;57:679–686.
   PubMed Web of Science ®Google Scholar
• Asoh S, Ohsawa I, Mori T, et al. Protection against ischemic brain injury by protein therapeutics. Proc Natl Acad Sci USA. 2002;99:17107–17112.
   PubMed Web of Science ®Google Scholar
• Kilic E, Dietz GP, Hermann DM, et al. Intravenous TAT-Bcl-Xl is protective after middle cerebral artery occlusion in mice. Ann Neurol. 2002;52:617–622.
   PubMed Web of Science ®Google Scholar
• Yang D, Sun YY, Lin X, et al. Intranasal delivery of cell-penetrating anti-NF-kappaB peptides (Tat-NBD) alleviates infection-sensitized hypoxic-ischemic brain injury. Exp Neurol. 2013;247:447–455.
   PubMed Web of Science ®Google Scholar
• Guidotti G, Rossi D. Cell-penetrating peptides: from basic research to clinics. Trends Pharmacol Sci. 2017;38:406–424.
   PubMed Web of Science ®Google Scholar
• Peterson JM, Kline W, Canan BD, et al. Peptide-based inhibition of NF-κB rescues diaphragm muscle contractile dysfunction in a murine model of Duchenne muscular dystrophy. Mol Med. 2011;17:508–515.
   PubMed Web of Science ®Google Scholar
• Tang J, Fu H, Kuang Q, et al. A detachable coating of cholesterol-anchored PEG improves tumor targeting of cell-penetrating peptide-modified liposomes. Acta Pharm Sin B. 2014;4:67–73.
   PubMed Web of Science ®Google Scholar
• Phelan A, Elliott G, O’Hare P. Intercellular delivery of functional p53 by the herpesvirus protein VP22. Nat Biotechnol. 1998;16:440–443.
   PubMed Web of Science ®Google Scholar
• Meyer-Losic F, Nicolazzi C, Quinonero J, et al. DTS-108, a novel peptidic prodrug of SN38: in vivo efficacy and toxicokinetic studies. Clin Cancer Res. 2008;14:2145–2153.
   PubMed Web of Science ®Google Scholar
• Hosotani R, Miyamoto Y, Fujimoto K, et al. Trojan p16 peptide suppresses pancreatic cancer growth and prolongs survival in mice. Clin Cancer Res. 2002;8:1271–1276.
   PubMed Web of Science ®Google Scholar
• Hosseini A, Lattanzio FA, Samudre SS, et al. Efficacy of a phosphorodiamidate morpholino oligomer antisense compound in the inhibition of corneal transplant rejection in a rat cornea transplant model. J Ocul Pharmacol Ther. 2012;28:194–201.
   PubMed Web of Science ®Google Scholar
• Hoffmann K, Juraja SM, Cunningham PT, et al. A platform for discovery of functional cell-penetrating peptides for efficient multi-cargo intracellular delivery. Sci Rep. 2018;8:12538.
   PubMed Web of Science ®Google Scholar
• Lebleu B, Moulton HM, Abes R, et al. Cell penetrating peptide conjugates of steric block oligonucleotides. Adv Drug Deliv Rev. 2008;60:517–529.
   PubMed Web of Science ®Google Scholar
• Kinali M, Arechavala-Gomeza V, Feng L, et al. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol. 2009;8:918–928.
   PubMed Web of Science ®Google Scholar
• Rothbard JB, Garlington S, Lin Q, et al. Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation. Nat Med. 2000;6:1253–1257.
   PubMed Web of Science ®Google Scholar
• Vivès E, Schmidt J, Pèlegrin A. Cell-penetrating and cell-targeting peptides in drug delivery. Biochim Biophys Acta. 2008;1786:126–138.
   PubMed Web of Science ®Google Scholar
• Abes R, Arzumanov AA, Moulton HM, et al. Cell penetrating peptide-based delivery of oligonucleotides: an overview. Biochem Soc Trans. 2007;35:775–779.
   PubMed Web of Science ®Google Scholar
• Bates E, Bode C, Costa M, et al. Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. Circulation. 2008;117:886–896.
   PubMed Web of Science ®Google Scholar
• Cousins MJ, Pickthorn K, Huang S, et al. The safety and efficacy of KAI-1678-an inhibitor of epsilon protein kinase C (εPKC) versus lidocaine and placebo for the treatment of postherpetic neuralgia: a crossover study design. Pain Med. 2013;14:533–540.
   PubMed Web of Science ®Google Scholar
• Warso MA, Richards JM, Mehta D, et al. A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumors. Br J Cancer. 2013;108:1061–1070.
   PubMed Web of Science ®Google Scholar
• Suckfuell M, Lisowska G, Domka W, et al. Efficacy and safety of AM-111 in the treatment of acute sensorineural hearing loss: a double-blind, randomized, placebo-controlled Phase II study. Otol Neurotol. 2014;35:1317–1326.
   PubMed Web of Science ®Google Scholar
• Garcia-Murray E. Safety and efficacy of RT002, an injectable botulinum toxin type A, for treating glabellar lines: results of a phase 1/2, open-label, sequential dose-escalation study. Dermatol Surg. 2015;41:S47–S55.
   PubMed Web of Science ®Google Scholar
• Deloche C, Lopez-Lazaro L, Mouz S, et al. XG-102 administered to healthy male volunteers as a single intravenous infusion: a randomized, double-blind, placebo-controlled, dose-escalating study. Pharmacol Res Perspect. 2014;2:e00020.
   PubMedGoogle Scholar
• Touchard E, Omri S, Naud MC, et al. A peptide inhibitor of c-Jun N-terminal kinase for the treatment of endotoxin-induced uveitis. Invest Ophthalmol Vis Sci. 2010;51:4683–4693.
   PubMed Web of Science ®Google Scholar
• El Zaoui I, Touchard E, Berdugo M, et al. Subconjunctival injection of XG-102, a c-Jun N-terminal kinase inhibitor peptide, in the treatment of endotoxin-induced uveitis in rats. J Ocul Pharmacol Ther. 2015;31:17–24.
   PubMed Web of Science ®Google Scholar
• Sawant RR, Patel NR, Torchilin VP. Therapeutic delivery using cell-penetrating peptides. Eur J Nanomed. 2013;5:141–158.
   Google Scholar
• Jankovic J, Truong D, Patel AT, et al. Injectable Daxibotulinumtoxin A in cervical dystonia: a phase 2 dose-escalation multicenter study. Mov Disord Clin Pract. 2018;5:273–282.
   PubMed Web of Science ®Google Scholar
• Borsello T, Clarke PG, Hirt L, et al. A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia. Nat Med. 2003;9:1180–1186.
   PubMed Web of Science ®Google Scholar
• Bright R, Raval AP, Dembner JM, et al. Protein kinase C delta mediates cerebral reperfusion injury in vivo. J Neurosci. 2004;24:6880–6888.
   PubMed Web of Science ®Google Scholar
• Martorana F, Brambilla L, Valori CF, et al. The BH4 domain of Bcl-XL rescues astrocyte degeneration in amyotrophic lateral sclerosis by modulating intracellular calcium signals. Hum Mol Genet. 2012;21:826–840.
   PubMed Web of Science ®Google Scholar
• Sclip A, Tozzi A, Abaza A, et al. c-Jun N-terminal kinase has a key role in Alzheimer disease synaptic dysfunction in vivo. Cell Death Dis. 2014;5:e1019.
   PubMed Web of Science ®Google Scholar
• Delfin DA, Xu Y, Peterson JM, et al. Improvement of cardiac contractile function by peptide-based inhibition of NF-κB in the utrophin/dystrophin-deficient murine model of muscular dystrophy. J Transl Med. 2011;9:68.
   PubMed Web of Science ®Google Scholar
• Zhang YE, Wang JN, Tang JM, et al. In vivo protein transduction: delivery of PEP-1-SOD1 fusion protein into myocardium efficiently protects against ischemic insult. Mol Cells. 2009;27:159–166.
   PubMed Web of Science ®Google Scholar
• Huang GQ, Wang JN, Tang JM, et al. The combined transduction of copper, zinc-superoxide dismutase and catalase mediated by cell-penetrating peptide, PEP-1, to protect myocardium from ischemia-reperfusion injury. J Transl Med. 2011;9:73.
   PubMed Web of Science ®Google Scholar
• Boisguerin P, Redt-Clouet C, Franck-Miclo A, et al. Systemic delivery of BH4 anti-apoptotic peptide using CPPs prevents cardiac ischemia–reperfusion injuries in vivo. J Control Release. 2011;156:146–153.
   PubMed Web of Science ®Google Scholar
• Snyder EL, Meade BR, Saenz CC, et al. Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide. PLoS Biol. 2004;2:e36.
   PubMed Web of Science ®Google Scholar
• Crombez L, Morris MC, Dufort S, et al. Targeting cyclin B1 through peptide-based delivery of siRNA prevents tumour growth. Nucleic Acids Res. 2009;37:4559–4569.
   PubMed Web of Science ®Google Scholar
• Michiue H, Eguchi A, Scadeng M, et al. Induction of in vivo synthetic lethal RNAi responses to treat glioblastoma. Cancer Biol Ther. 2009;8:2306–2313.
   PubMed Web of Science ®Google Scholar
• Morishita M, Peppas NA. Is the oral route possible for peptide and protein drug delivery? Drug Discov Today. 2006;11:905–910.
   PubMed Web of Science ®Google Scholar
• Rousselle C, Smirnova M, Clair P, et al. Enhanced delivery of doxorubicin into the brain via a peptide vector-mediated strategy: saturation kinetics and specificity. J Pharmacol Exp Ther. 2001;296:124–131.
   PubMed Web of Science ®Google Scholar
• Rousselle C, Clair P, Temsamani J, et al. Improved brain delivery of benzylpenicillin with a peptide vector-mediated strategy. J Drug Target. 2002;10:309–315.
   PubMed Web of Science ®Google Scholar
• Schroeder U, Schroeder H, Sabel BA. Body distribution of 3HH-labelled dalargin bound to poly (butyl cyanoacrylate) nanoparticles after IV injections to mice. Life Sci. 2000;66:495–502.
   PubMed Web of Science ®Google Scholar
• Hotchkiss RS, McConnell KW, Bullok K, et al. TAT-BH4 and TAT-Bcl-xL peptides protect against sepsis-induced lymphocyte apoptosis in vivo. J Immunol. 2006;176:5471–5477.
   PubMed Web of Science ®Google Scholar
• Koshkaryev A, Piroyan A, Torchilin VP. Bleomycin in octaarginine-modified fusogenic liposomes results in improved tumor growth inhibition. Cancer Lett. 2013;334:293–301.
   PubMed Web of Science ®Google Scholar
• Tan M, Lan KH, Yao J, et al. Selective inhibition of ErbB2-overexpressing breast cancer in vivo by a novel TAT-based ErbB2-targeting signal transducers and activators of transcription 3-blocking peptide. Cancer Res. 2006;66:3764–3772.
   PubMed Web of Science ®Google Scholar
• Niesner U, Halin C, Lozzi L, et al. Quantitation of the tumor-targeting properties of antibody fragments conjugated to cell-permeating HIV-1 TAT peptides. Bioconjug Chem. 2002;13:729–736.
   PubMed Web of Science ®Google Scholar
• Myrberg H, Zhang L, Mae M, et al. Design of a tumor-homing cell penetrating peptide. Bioconjug Chem. 2008;19:70–75.
   PubMed Web of Science ®Google Scholar
• Bowne WB, Michl J, Bluth MH, et al. Novel peptides from the RAS-p21 and p53 proteins for the treatment of cancer. Cancer Ther. 2007;5:331–344.
   Google Scholar
• Michl J, Scharf B, Schmidt A, et al. PNC-28, a p53-derived peptide that is cytotoxic to cancer cells, blocks pancreatic cancer cell growth in vivo. Int J Cancer. 2006;119:1577–1585.
   PubMed Web of Science ®Google Scholar
• Ru Q, Shang BY, Miao QF, et al. A cell penetrating peptide-integrated and enediyne-energized fusion protein shows potent antitumor activity. Eur J Pharm Sci. 2012;47:781–789.
   PubMed Web of Science ®Google Scholar
• Perea SE, Reyes O, Puchades Y, et al. Antitumor effect of a novel proapoptotic peptide that impairs the phosphorylation by the protein kinase 2 (casein kinase 2). Cancer Res. 2004;64:7127–7129.
   PubMed Web of Science ®Google Scholar
• Lee JY, Choi YS, Suh JS, et al. Cell-penetrating chitosan/doxorubicin/TAT conjugates for efficient cancer therapy. Int J Cancer. 2011;128:2470–2480.
   PubMed Web of Science ®Google Scholar
• Gu G, Gao X, Hu Q, et al. The influence of the penetrating peptide iRGD on the effect of paclitaxel-loaded MT1-AF7p-conjugated nanoparticles on glioma cells. Biomaterials. 2013;34:5138–5148.
   PubMed Web of Science ®Google Scholar
• Hu Q, Gao X, Gu G, et al. Glioma therapy using tumor homing and penetrating peptide-functionalized PEG-PLA nanoparticles loaded with paclitaxel. Biomaterials. 2013;34:5640–5650.
   PubMed Web of Science ®Google Scholar
• Jain M, Chauhan SC, Singh AP, et al. Penetratin improves tumor retention of single-chain antibodies: a novel step toward optimization of radioimmunotherapy of solid tumors. Cancer Res. 2005;65:7840–7846.
   PubMed Web of Science ®Google Scholar
• Johnson LN, Cashman SM, Kumar-Singh R. Cell-penetrating peptide for enhanced delivery of nucleic acids and drugs to ocular tissues including retina and cornea. Mol Ther. 2008;16:107–114.
   PubMed Web of Science ®Google Scholar
• Cashman SM, Sadowski SL, Morris DJ, et al. Intercellular trafficking of adenovirus-delivered HSV VP22 from the retinal pigment epithelium to the photoreceptors-implications for gene therapy. Mol Ther. 2002;6:813–823.
   PubMed Web of Science ®Google Scholar
• Cashman SM, Morris DJ, Kumar-Singh R. Evidence of protein transduction but not intercellular transport by proteins fused to HIV tat in retinal cell culture and in vivo. Mol Ther. 2003;8:130–142.
   PubMed Web of Science ®Google Scholar
• D’Astolfo DS, Pagliero RJ, Pras A, et al. Efficient intracellular delivery of native proteins. Cell. 2015;161:674–690.
   PubMed Web of Science ®Google Scholar